#NS5A inhibitor

The Food and Drug Administration has approved AbbVie’s once-daily Mavyret to treat all six major genotypes of hepatitis C virus (HCV).

It approved 12 weeks of Gilead Sciences’ Vosevi for the re-treatment of adults with all genotypes of HCV who do not have cirrhorsis.

The triple-drug regimen comes in a once-daily single tablet.

EDP-239, a new NS5A inhibitor hepatitis C treatment from Enanta, showed promise in a small single-dose monotherapy study.

Abbott has announced Phase III trials of three direct acting agents, ABT-450/r, ABT-267, ABT-333, which together have shown high cure rates in...

A combination of daclatasvir and sofosbuvir produced cures in more than 93 percent of hepatitis C patients, with or without the addition of ri...

Gilead Sciences? pair of investigatory hepatitis C virus therapies led to a 100 percent cure rate among a small cohort of patients.

Abbott Laboratories’ three-drug regimen cured 97 percent of treatment-naive hepatitis C patients and 93 percent of those who had failed a prev...

ACH-3102, a hepatitis C drug under development by Achillion Pharmaceuticals, has received Fast Track status from the FDA, according to an...

A 24-week, interferon-free regimen pairing two drugs from Bristol-Myers Squibb--60 milligrams (mg) of daclatasvir, a once-daily NS5a...

Combining two experimental oral hepatitis C drugs from Bristol-Myers Squibb (BMS)--daclatasvir, a once-daily NS5a inhibitor, and...

Adding BMS-790052, an experimental hepatitis C drug being developed by Bristol-Myers Squibb, to pegylated interferon and ribavirin...

Pharmasset Inc. has started its Phase II clinical trial investigating the combination of its nucleotide polymerase inhibitor PSI-7977 and...

In what is being heralded as a hepatitis C virus (HCV) treatment research breakthrough, a clinical trial evaluating two oral medications being...